First-in-Class VS Me-Too Launch Differences and the Role of Content, Hyperpersonalization, and Technology with Frank Dolan, Founder and CEO of ARSENAL
Listen now
Description
First-in-class medications are often referred to as innovative treatment alternatives. But innovation might scare and push away some HCPs and patients. In this episode of Pharma Launch Secrets, Bozidar is joined by Frank Dolan, Founder, and CEO of ARSENAL
More Episodes
In this episode of Pharma Launch Secrets, Bozidar speaks with Nancy Phelan, senior VP at Indegene.
Published 01/12/24
Published 01/12/24
In this special compilation episode, we will take you back to revisit some of the most enlightening conversations, innovative strategies, and motivating stories since our beginning.
Published 09/28/23
Links
Twitter
Facebook
Instagram
Patreon
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
